NEWS & ACTIVITIES

From December 5 to 7, 2025 , EG Bio participated in iSWAM Jakarta 2025  alongside Genèse Labs France , advancing its strategic expansion in Indonesia and ASEAN markets. iSWAM (International Symposium on Aesthetic Medicine) typically hosts 2,500+ doctors , 150+ exhibitors , and participants from across the Asia-Pacific region, making it a key congress for professional aesthetic medicine. At iSWAM Jakarta 2025, EG Bio and Genèse Labs France showcased advanced regenerative and i

From October 21 to 23, 2025 , EG Bio participated in InterCHARM Moscow 2025  together with Genèse Labs France , reinforcing engagement with CIS and Eastern European partners. InterCHARM Moscow is one of the largest professional beauty and aesthetics exhibitions in the region, typically attracting 60,000+ visitors , 1,000+ exhibitors , and companies from 40+ countries . At the exhibition, EG Bio and Genèse Labs France presented their latest portfolio developments and met with

From October 16 to 18, 2025 , EG Bio participated in AMWC Latin America 2025  in Medellín together with Genèse Labs France , continuing its structured expansion across Latin American markets. AMWC Latin America typically welcomes 3,000+ medical professionals , 200+ exhibitors , and participants from across Central and South America, making it one of the region’s most important aesthetic medicine congresses. At the congress, EG Bio and Genèse Labs France showcased their latest

From July 24 to 26, 2025 , EG Bio attended Vietbeauty 2025  together with Genèse Labs France , strengthening its footprint in Southeast Asia. Vietbeauty is one of Vietnam’s leading beauty and aesthetics exhibitions, typically hosting 10,000+ trade visitors , 600+ exhibitors , and participants from 25+ countries , serving as a key gateway to ASEAN markets. During the exhibition, EG Bio and Genèse Labs France showcased their newest product innovations and engaged with regional

From April 14 to 16, 2025 , EG Bio participated in Dubai Derma 2025  alongside Genèse Labs France , strengthening engagement across Middle Eastern markets. Dubai Derma is the largest dermatology and aesthetic exhibition in the Middle East, typically attracting 20,000+ visitors , 1,500+ brands , and professionals from 100+ countries . The exhibition plays a central role in shaping regional distribution frameworks, regulatory pathways, and commercial partnerships. At Dubai Derm

From March 27 to 29, 2025 , EG Bio Co., Ltd.  participated in AMWC Monaco 2025  together with its strategic partner Genèse Labs France , reinforcing its presence at the most influential global event in medical aesthetics. AMWC Monaco is widely regarded as the world’s leading aesthetic and anti-aging medicine congress, typically welcoming 15,000+ attendees , 900+ exhibiting companies , and participants from 130+ countries . The event combines high-level scientific education wi

Expanding ancillary products for professional aesthetic procedures In February 2025 , EG Bio Co., Ltd.  expanded its professional product lineup with the introduction of the X-Caine  and X-Pro  numbing cream series, strengthening its ancillary offerings for aesthetic procedures. The X-Caine and X-Pro series were introduced to support procedural comfort across a wide range of professional aesthetic treatments. By adding these products to its portfolio, EG Bio aims to provide d

Introducing a new hyaluronic acid filler line for international markets In January 2025 , Rèluma HA Filler , a new hyaluronic acid filler line developed by Genèse Labs France , was officially launched and added to EG Bio Co., Ltd. ’s global distribution portfolio. Rèluma HA Filler was introduced as part of Genèse Labs France’s expanding injectable portfolio, designed for professional aesthetic applications and structured international market entry. The product line reflects a

From November 21 to 23, 2024 , EG Bio participated in AMWC Asia 2024  in Bangkok, continuing its active engagement with distributors and professionals across the Asia-Pacific region. During the congress, EG Bio held meetings with partners from multiple Asian markets to discuss distribution frameworks, market access strategies, and long-term collaboration opportunities. Discussions focused on aligning product portfolios with regional needs and supporting sustainable growth acr

From November 13 to 15, 2024 , EG Bio attended Cosmoprof Asia 2024  in Hong Kong, one of the leading international exhibitions for the beauty and aesthetics industry, bringing together companies and professionals from Asia, Europe, and other global markets. Throughout the exhibition, EG Bio met with existing partners and prospective distributors, engaging in discussions related to international distribution strategies, portfolio development, and regional market expectations.

Dual-type exosome solutions strengthen regenerative aesthetic offerings In November 2024, Exoluma™ , an advanced exosome-based aesthetic product line developed by Genèse Labs France , was officially launched and added to EG Bio Co., Ltd. ’s global distribution portfolio. Exoluma™ represents the next generation of regenerative aesthetic solutions, designed to support skin rejuvenation and cellular renewal. The line includes two distinct formulations , each developed to meet sp

From October 17 to 19, 2024 , EG Bio Co., Ltd.  participated in AMWC Latin America 2024 , held in Medellín, Colombia, as part of its continued strategy to strengthen engagement across Colombian and broader Latin American markets. During the congress, EG Bio held in-depth discussions with regional distributors, clinic groups, and industry professionals, focusing on market-specific requirements, distribution structures, and long-term cooperation models. Particular attention was

In April 2024 , EG Bio Co., Ltd.  expanded its international aesthetic portfolio with the introduction of Citrus Bottle , a product developed by Genèse Labs France , into its global distribution lineup. Citrus Bottle was selected to complement EG Bio’s existing aesthetic offerings, strengthening the company’s presence in the fat-dissolving and body-contouring category. Through its established B2B distribution network, EG Bio supports the structured market introduction and int

Supporting expansion in regulated international markets In February 2024 , EG Bio Co., Ltd.  announced that Edel X™ HA Filler  has successfully received CE certification , marking an important step in the product’s expansion into regulated international markets, including Europe. The CE certification confirms that Edel X™ HA Filler meets applicable European regulatory requirements, supporting its distribution within CE-recognized markets. This milestone strengthens EG Bio’s a

In January 2024, Proluma PDLLA, a collagen biostimulator developed by Genèse Labs France, was added to EG Bio Co., Ltd.’s global distribution portfolio as part of its ongoing portfolio expansion strategy. Proluma PDLLA was introduced to strengthen EG Bio’s offering in the biostimulator category, supporting professional aesthetic treatments focused on long-term skin quality improvement and collagen stimulation. Through its established B2B network, EG Bio supports the struct

In November 2023, EG Bio Co., Ltd. officially launched Edel X HA Filler, marking an important milestone in the expansion of the company’s proprietary aesthetic product lineup. The launch of Edel X reflects EG Bio’s strategic focus on developing and introducing its own brands alongside its global distribution activities. With Edel X, EG Bio expands its portfolio with a hyaluronic acid–based filler designed for professional aesthetic markets and international distribution.

A strategic body filler solution for the Middle East & CIS market In October 2023, RG60 Body Filler  was officially launched by Genèse Labs France  and added to EG Bio Co., Ltd.’s distribution portfolio as part of its international expansion strategy. RG60 Body Filler was introduced as a strategic product designed to address market-specific requirements, with particular focus on the Middle East & CIS regions. Following its launch, EG Bio began supporting global distribution a

EG Bio Co., Ltd. announces the establishment of a strategic distribution partnership with Genèse Labs France , aimed at strengthening global market access and long-term cooperation in the medical aesthetics sector. Under this partnership, EG Bio will support the international distribution and market development  of selected Genèse Labs France products, leveraging its global B2B network, regional market experience, and established relationships with distributors and profession